glp-1 and cardiovascular benefits drawbacks of receptor agonist use. Abbreviations: SGLTi and GLP-1 in HF

Shehadeh N, Zuckerman-Levin N, Said W, Zolotov S, Elemy A

Manish Sahni, MD , provides personalized care to help patients safely and effectively incorporate this FDA-approved option into their weight loss journey

Pharmacological inhibition of the PI3K/mTOR pathway abolished such effects, suggesting that the metabolic actions of GLP-1 depend on mTOR activity

Comparative metabolic and hepatic effects of GLP-1-based mono-, dual-, and triple-agonist therapies GLP-1 receptor signaling Intestinal L-cells serve as the primary source of GLP-1 synthesis, which operates via G-protein coupled receptors present in pancreatic beta cells, gastrointestinal and central neural systems, cardiac tissues, and kidneys [26]

Improved kidney function: Recent developments in the management of T2D have identified the use of GLP-1s to reduce the progression of kidney disease in individuals with diabetes

Adjusting Your GLP-1 Dose: What to Expect Over Time Dose adjustments are a normal part of GLP-1 therapy and should always be guided by your healthcare professional